Table 2 Overall survival for different patient groups in Study 301
Progression due to new metastases | Progression due to pre-existing lesions | No reported disease progression | |||||||
|---|---|---|---|---|---|---|---|---|---|
Eribulin | Capecitabine | Total | Eribulin | Capecitabine | Total | Eribulin | Capecitabine | Total | |
(n = 216) | (n = 204) | (N = 420) | (n = 131) | (n = 112) | (N = 243) | (n = 207) | (n = 232) | (N = 439) | |
Median OS, months (95 % CI) | 14.6 (12.4, 17.1) | 11.3 (9.2, 13.4) | 13.0 (11.6, 14.4) | 18.0 (14.7, 19.7) | 16.7 (14.2, 19.9) | 17.1 (15.5, 19.4) | 17.6 (15.4, 20.7) | 16.8 (14.3, 19.1) | 16.9 (15.7, 18.9) |
HR eribulin vs. capecitabine (95 % CI) | 0.75 (0.61, 0.93) | – | 0.92 (0.69, 1.23) | – | 0.91 (0.73, 1.15) | – | |||
p value | 0.008 | – | 0.57 | – | 0.44 | – | |||